Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
GLP-1 Receptor Agonist Global Market Report 2025
Request Sample Buy Now
Global GLP-1 Receptor Agonist Market Report 2025

Report Price : $4490.00

Pages : 200

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

GLP-1 Receptor Agonist Global Market Report 2025

By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs ), By Route Of Administration (Parenteral, Oral ), By End Users (Hospitals, Surgical Clinics, Other Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

GLP-1 Receptor Agonist Market Overview

• GLP-1 Receptor Agonist market size has reached to $13.58 billion in 2024

• Expected to grow to $17.36 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%

• Growth Driver: Surging Diabetes Cases Fuel Growth In Glp-1 Receptor Agonist Market

• Market Trend: Innovative Breakthroughs Transform The Glp-1 Receptor Agonist Market

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under GLP-1 Receptor Agonist Market?

A GLP-1 receptor agonist is a type of medication that stimulates insulin release at high blood glucose levels and suppresses glucagon secretion under low blood glucose conditions. They are used to treat type 2 diabetes mellitus.

The main drug class of GLP-1 receptor agonist is liraglutide, dulaglutide, lixisenatide, and others. Liraglutide is a GLP-1 receptor agonist that acts by helping the pancreas to release the right amount of insulin when blood sugar levels are high. The route of administration involved is parenteral, and oral which are used by hospitals, surgical clinics, and others.

GLP-1 Receptor Agonist Global Market Report 2025 Market Size and growth rate 2025 to 2029: Graph

What Is The GLP-1 Receptor Agonist Market Size 2025 And Growth Rate?

The GLP-1 receptor agonist market size has grown steadily in recent years. It will grow from $13.58 billion in 2024 to $14.09 billion in 2025 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to rising diabetes prevalence, clinical efficacy, patient awareness and acceptance, global health initiatives, patient preference for injectable therapies.

What Is The GLP-1 Receptor Agonist Market Growth Forecast?

The GLP-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to $17.36 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to increasing emphasis on lifestyle management, growing personalized medicine approaches, expanding indications, development of next-generation products, integration into combination therapies. Major trends in the forecast period include introduction of oral formulations, focus on combination therapies, strategic partnerships and collaborations, reimbursement policies and access, patient-centric approaches.

The forecast of 5.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade restrictions could hinder U.S. diabetes and obesity treatment by inflating prices of semaglutide and liraglutide injectable pens sourced from Denmark and Austria, reducing patient access to weight management therapies and raising endocrinology care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The GLP-1 Receptor Agonist Market Segmented?

1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs

2) By Route Of Administration: Parenteral, Oral

3) By End Users: Hospitals, Surgical Clinics, Other Users

Subsegments:

1) By Exenatide: Byetta, Bydureon

2) By Liraglutide: Victoza, Saxenda

3) By Dulaglutide: Trulicity

4) By Lixisenatide: Adlyxin

5) By Other Drugs: Semaglutide, Tirzepatide, Others

What Is Driving The GLP-1 Receptor Agonist Market? Surging Diabetes Cases Fuel Growth In Glp-1 Receptor Agonist Market

The rising prevalence of diabetes is expected to propel the GLP-1 receptor agonist market going forward. Diabetes is a chronic illness that develops when the pancreas either produces insufficient amounts of insulin or when the body cannot properly utilize the insulin that it does. High blood sugar is a symptom of the metabolic disorder diabetes mellitus. GLP-1 receptor agonist is used in diabetes to stimulate the body to produce more insulin, which helps to lower blood sugar levels, so the rising prevalence of diabetes will propel the market growth. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of diabetes is driving the GLP-1 receptor agonist industry.

What Is Driving The GLP-1 Receptor Agonist Market? Rising Obesity Epidemic Fuels Surge In The Glp-1 Receptor Agonist Market

The increasing cases of obesity are expected to boost the growth of the GLP-1 receptor agonist market going forward. Obesity refers to a medical condition characterized by the excessive accumulation of body fat, often resulting in an individual having a body mass index (BMI) of 30 or higher and is associated with various health risks and complications. GLP-1 receptor agonists (GLP-1RAs) are a class of medications that have been shown to be effective in treating obesity by mimicking the effects of a naturally occurring hormone called GLP-1, which helps to regulate appetite and blood sugar levels. For instance, in March 2022, according to the World Health Organization, a Switzerland-based public health organization, over 1 billion individuals globally were affected by obesity, comprising 650 million adults, 340 million adolescents, and 39 million children, with this figure continuing to rise. Further, it is estimated that around 167 million people are expected to experience compromised health due to being overweight or obese. Therefore, the increasing cases of obesity are driving the growth of the GLP-1 receptor agonist industry.

Who Are The Major Players In The Global GLP-1 Receptor Agonist Market?

Major companies operating in the GLP-1 receptor agonist market include Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG

What Are The Key Trends Of The Global GLP-1 Receptor Agonist Market? Innovative Breakthroughs Transform The Glp-1 Receptor Agonist Market

Product innovations are a key trend gaining popularity in the GLP-1 receptor agonist market. Major companies operating in the GLP-1 receptor agonist market are focused on developing innovative solutions to strengthen their position. For instance, in May 2022, Eli Lilly and Company, a US-based pharmaceutical company that creates medicines that make life better for people, launched the FDA-approved new Mounjaro, a GIP and GLP-1 receptor agonist. It is specially designed using a single molecule that turns on the body's receptors for the incretin hormones GIP and GLP-1. It is available as a pen auto-injector with a pre-attached, hidden needle that patients do not need to handle or see, and it comes in 6 doses.

What Are The Key Trends Of The Global GLP-1 Receptor Agonist Market? Sustained-Release Glp-1 Receptor Agonists Are Gaining Popularity

Major companies operating in the GLP-1 receptor agonist market are focused on developing sustained-release GLP-1 receptor agonists to gain a competitive edge in the market. Sustained-release GLP-1 receptor agonists (GLP-1RAs) are a type of medication that slowly releases GLP-1RA into the bloodstream over time, which allows for longer-lasting effects and less frequent injections compared to traditional GLP-1RAs. For instance, in April 2023, Mitsubishi Tanabe Pharma Corporation, a Japan-based pharmaceuticals company, launched Mounjaro 2.5 mg or 5 mg Ateos. It is the world's first sustained-release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes that activates both the GLP-1 and GIP receptors. The GLP-1 receptor is involved in regulating blood sugar levels, while the GIP receptor is involved in stimulating insulin secretion and reducing appetite.

Need data on a specific region in this market?
Request Customisation

GLP-1 Receptor Agonist Market Merger And Acquisition: Sanofi Strengthens Biologics Portfolio With Acquisition Of Amunix Pharmaceuticals Inc.

In February 2022, Sanofi S.A., a France-based pharmaceutical and healthcare company that provides life-changing treatments, acquired Amunix Pharmaceuticals Inc. for an undisclosed amount. Through this acquisition, combined resources with Sanofi are expected to provide access to various products and technologies to Sanofi that can deliver next-generation conditionally activated biologics. Amunix Pharmaceuticals Inc. is a US-based immuno-oncology company that develops (GLP-1) receptor agonists and transformative therapies for cancer.

Regional Analysis For The Global GLP-1 Receptor Agonist Market

North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the GLP-1 Receptor Agonist Market?

The GLP-1 receptor agonist market consists of sales of dulaglutide, bydureon b-cise, exenatide, and semaglutide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the GLP-1 Receptor Agonist Industry?

The glp-1 receptor agonist market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glp-1 receptor agonist industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

GLP-1 Receptor Agonist Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $14.09 billion
Revenue Forecast In 2034 $17.36 billion
Growth Rate CAGR of 5.4% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users Subsegments: 1) By Exenatide: Byetta, Bydureon
2) By Liraglutide: Victoza, Saxenda
3) By Dulaglutide: Trulicity
4) By Lixisenatide: Adlyxin
5) By Other Drugs: Semaglutide, Tirzepatide, Others
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. GLP-1 Receptor Agonist Market Characteristics

3. GLP-1 Receptor Agonist Market Trends And Strategies

4. GLP-1 Receptor Agonist Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global GLP-1 Receptor Agonist Growth Analysis And Strategic Analysis Framework

5.1. Global GLP-1 Receptor Agonist PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global GLP-1 Receptor Agonist Market Growth Rate Analysis

5.4. Global GLP-1 Receptor Agonist Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global GLP-1 Receptor Agonist Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global GLP-1 Receptor Agonist Total Addressable Market (TAM)

6. GLP-1 Receptor Agonist Market Segmentation

6.1. Global GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Exenatide

Liraglutide

Dulaglutide

Lixisenatide

Other Drugs

6.2. Global GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Parenteral

Oral

6.3. Global GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Surgical Clinics

Other Users

6.4. Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Exenatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Byetta

Bydureon

6.5. Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Victoza

Saxenda

6.6. Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Dulaglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Trulicity

6.7. Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Lixisenatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Adlyxin

6.8. Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Semaglutide

Tirzepatide

Others

7. GLP-1 Receptor Agonist Market Regional And Country Analysis

7.1. Global GLP-1 Receptor Agonist Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global GLP-1 Receptor Agonist Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific GLP-1 Receptor Agonist Market

8.1. Asia-Pacific GLP-1 Receptor Agonist Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China GLP-1 Receptor Agonist Market

9.1. China GLP-1 Receptor Agonist Market Overview

9.2. China GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India GLP-1 Receptor Agonist Market

10.1. India GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan GLP-1 Receptor Agonist Market

11.1. Japan GLP-1 Receptor Agonist Market Overview

11.2. Japan GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia GLP-1 Receptor Agonist Market

12.1. Australia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia GLP-1 Receptor Agonist Market

13.1. Indonesia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea GLP-1 Receptor Agonist Market

14.1. South Korea GLP-1 Receptor Agonist Market Overview

14.2. South Korea GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe GLP-1 Receptor Agonist Market

15.1. Western Europe GLP-1 Receptor Agonist Market Overview

15.2. Western Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK GLP-1 Receptor Agonist Market

16.1. UK GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany GLP-1 Receptor Agonist Market

17.1. Germany GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France GLP-1 Receptor Agonist Market

18.1. France GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy GLP-1 Receptor Agonist Market

19.1. Italy GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain GLP-1 Receptor Agonist Market

20.1. Spain GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe GLP-1 Receptor Agonist Market

21.1. Eastern Europe GLP-1 Receptor Agonist Market Overview

21.2. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia GLP-1 Receptor Agonist Market

22.1. Russia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America GLP-1 Receptor Agonist Market

23.1. North America GLP-1 Receptor Agonist Market Overview

23.2. North America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA GLP-1 Receptor Agonist Market

24.1. USA GLP-1 Receptor Agonist Market Overview

24.2. USA GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada GLP-1 Receptor Agonist Market

25.1. Canada GLP-1 Receptor Agonist Market Overview

25.2. Canada GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America GLP-1 Receptor Agonist Market

26.1. South America GLP-1 Receptor Agonist Market Overview

26.2. South America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil GLP-1 Receptor Agonist Market

27.1. Brazil GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East GLP-1 Receptor Agonist Market

28.1. Middle East GLP-1 Receptor Agonist Market Overview

28.2. Middle East GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa GLP-1 Receptor Agonist Market

29.1. Africa GLP-1 Receptor Agonist Market Overview

29.2. Africa GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. GLP-1 Receptor Agonist Market Competitive Landscape And Company Profiles

30.1. GLP-1 Receptor Agonist Market Competitive Landscape

30.2. GLP-1 Receptor Agonist Market Company Profiles

30.2.1. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AstraZeneca Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

31. GLP-1 Receptor Agonist Market Other Major And Innovative Companies

31.1. Hanmi Pharm Co. Ltd.

31.2. Pfizer Inc.

31.3. Amgen Inc.

31.4. Innovent Biologics Inc.

31.5. Jiangsu Hengrui Medicine Co.

31.6. Sun Pharmaceuticals Industries Ltd.

31.7. PegBio Co. Ltd.

31.8. Zealand Pharma A/S

31.9. Bristol-Myers Squibb Company

31.10. Chongqing Lummy Pharmaceutical Co. Ltd.

31.11. Daiichi Sankyo Company Limited

31.12. Dong-A ST Co. Ltd.

31.13. Eisai Co. Ltd.

31.14. HanAll Biopharma Co. Ltd.

31.15. Ipsen SA

32. Global GLP-1 Receptor Agonist Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The GLP-1 Receptor Agonist Market

34. Recent Developments In The GLP-1 Receptor Agonist Market

35. GLP-1 Receptor Agonist Market High Potential Countries, Segments and Strategies

35.1 GLP-1 Receptor Agonist Market In 2029 - Countries Offering Most New Opportunities

35.2 GLP-1 Receptor Agonist Market In 2029 - Segments Offering Most New Opportunities

35.3 GLP-1 Receptor Agonist Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Exenatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Dulaglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Lixisenatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global GLP-1 Receptor Agonist Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global GLP-1 Receptor Agonist Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Novo Nordisk A/S Financial Performance
  • Table 80: Sanofi SA Financial Performance
  • Table 81: Eli Lilly and Company Financial Performance
  • Table 82: AstraZeneca Inc. Financial Performance
  • Table 83: Boehringer Ingelheim International GmbH Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Exenatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Dulaglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Lixisenatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global GLP-1 Receptor Agonist Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global GLP-1 Receptor Agonist Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Novo Nordisk A/S Financial Performance
  • Figure 80: Sanofi SA Financial Performance
  • Figure 81: Eli Lilly and Company Financial Performance
  • Figure 82: AstraZeneca Inc. Financial Performance
  • Figure 83: Boehringer Ingelheim International GmbH Financial Performance

Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Read More About Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Read More About Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Read More About Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

Read More About Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Blood And Blood Components Global Market Report 2025 – By Product (Whole Blood, Blood Components), By Blood Components (Red Blood Cells, Platelets, Plasma, White Blood Cells), By End-User (Hospitals, Ambulatory Surgical ...

View Report

Blood Group Typing Global Market Report 2025 – By Test Type (Antibody Screening, Cross-Matching Tests, ABO Tests, Antigen Typing, HLA Typing), By Product (Instruments, Reagents And Kits), By Techniques (Serology Tests, M...

View Report

Blood Glucose Meters Global Market Report 2025 – By Product type (Electrode Type Blood Glucose Meter, Photoelectric Blood Glucose Meter), By Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), By End Us...

View Report

Blood Cancer Drugs Global Market Report 2025 – By Blood Cancer Type (Leukemia, Lymphoma), By Drugs (Rituxan/Mabthera (Rituximab), Gleevec/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotin...

View Report

Blood Transfusion Diagnostics Global Market Report 2025 – By Type (Instruments and Kits, Reagents, Other Types), By Technology (Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test), By Applica...

View Report

Smarts Sports Equipment Global Market Report 2025 – By Product Type (Smart Balls, Smart Golf Sticks, Smart Hockey Sticks, Smart Racket And Bats, Others Products), By Connectivity Features (Smartphone Synchronization, Wir...

View Report

Dialysis Devices And Equipment Global Market Report 2025 – By Product (Hemodialysis Devices, Peritoneal Dialysis Devices, Continuous Renal Replacement Therapy (CRRT) Systems, Consumables), By Application (Serum And Blood...

View Report

Wireline Services Global Market Report 2025 – By Type (Electric Line, Slick Line), By Service Type (Intervention, Logging, Completion), By Hole Type (Open Hole, Cased Hole), By Location Of Deployment (Onshore, Offshore) ...

View Report

Frequently Asked Questions

A GLP-1 receptor agonist is a type of medication that stimulates insulin release at high blood glucose levels and suppresses glucagon secretion under low blood glucose conditions. They are used to treat type 2 diabetes mellitus. For further insights on this market, request a sample here

The market major growth driver - Surging Diabetes Cases Fuel Growth In Glp-1 Receptor Agonist Market. For further insights on this market, request a sample here

The GLP-1 receptor agonist market size has grown steadily in recent years. It will grow from $13.58 billion in 2024 to $14.09 billion in 2025 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to rising diabetes prevalence, clinical efficacy, patient awareness and acceptance, global health initiatives, patient preference for injectable therapies. The GLP-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to " $17.36 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to increasing emphasis on lifestyle management, growing personalized medicine approaches, expanding indications, development of next-generation products, integration into combination therapies. Major trends in the forecast period include introduction of oral formulations, focus on combination therapies, strategic partnerships and collaborations, reimbursement policies and access, patient-centric approaches. For further insights on this market, request a sample here

The glp-1 receptor agonist market covered in this report is segmented –
1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users Subsegments:
1) By Exenatide: Byetta, Bydureon
2) By Liraglutide: Victoza, Saxenda
3) By Dulaglutide: Trulicity
4) By Lixisenatide: Adlyxin
5) By Other Drugs: Semaglutide, Tirzepatide, Others For further insights on this market, request a sample here

North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the GLP-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the GLP-1 receptor agonist market include Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG . For further insights on this market, request a sample here.

Major trends in this market include Innovative Breakthroughs Transform The Glp-1 Receptor Agonist Market. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global GLP-1 Receptor Agonist Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top